LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 66

Search options

  1. Article ; Online: The Reply.

    Al-Obaidi, Mohanad M / Tanriover, Bekir / Zangeneh, Tirdad T

    The American journal of medicine

    2023  Volume 137, Issue 2, Page(s) e42

    Language English
    Publishing date 2023-05-16
    Publishing country United States
    Document type Letter
    ZDB-ID 80015-6
    ISSN 1555-7162 ; 1873-2178 ; 0002-9343 ; 1548-2766
    ISSN (online) 1555-7162 ; 1873-2178
    ISSN 0002-9343 ; 1548-2766
    DOI 10.1016/j.amjmed.2023.10.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Donor-derived Cell-free DNA Measurement in Kidney Transplant Patients Without Allograft Dysfunction: More Evidence and More Questions.

    Gupta, Gaurav / Tanriover, Bekir

    Transplantation

    2022  Volume 107, Issue 1, Page(s) 25–26

    MeSH term(s) Humans ; Kidney Transplantation/adverse effects ; Cell-Free Nucleic Acids ; Tissue Donors ; Transplantation, Homologous ; Graft Rejection/diagnosis ; Graft Rejection/prevention & control ; Graft Rejection/genetics ; Allografts
    Chemical Substances Cell-Free Nucleic Acids
    Language English
    Publishing date 2022-08-01
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 208424-7
    ISSN 1534-6080 ; 0041-1337
    ISSN (online) 1534-6080
    ISSN 0041-1337
    DOI 10.1097/TP.0000000000004268
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Contemporary Monoclonal Antibody Utilization in Glomerular Diseases.

    Mansour, Iyad / Murugapandian, Sangeetha / Tanriover, Bekir / Thajudeen, Bijin

    Mayo Clinic proceedings. Innovations, quality & outcomes

    2023  Volume 7, Issue 4, Page(s) 276–290

    Abstract: Therapeutic monoclonal antibodies (MAbs) have been one of the fastest growing drug classes in the past 2 decades and are indicated in the treatment of cancer, autoimmune disorders, solid organ transplantation, and glomerular diseases. The Food and Drug ... ...

    Abstract Therapeutic monoclonal antibodies (MAbs) have been one of the fastest growing drug classes in the past 2 decades and are indicated in the treatment of cancer, autoimmune disorders, solid organ transplantation, and glomerular diseases. The Food and Drug Administration has approved 100 MAbs between 1986 and 2021, and MAbs account for 20% of Food and Drug Administration's new drug approval every year. MAbs are preferred over traditional immunosuppressive agents because of their high specificity, reduced number of drug-drug interactions, and low toxicity, which make them a prime example of personalized medicine. In this review article, we provide an overview of the taxonomy, pharmacology, and therapeutic applications of MAbs in glomerular diseases. We searched the literature through PubMed using the following search terms:
    Language English
    Publishing date 2023-06-30
    Publishing country Netherlands
    Document type Journal Article ; Review
    ISSN 2542-4548
    ISSN (online) 2542-4548
    DOI 10.1016/j.mayocpiqo.2023.04.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Optimizing Utilization of Kidneys from Hepatitis C-Positive Kidney Donors.

    Ariyamuthu, Venkatesh K / Tanriover, Bekir

    Clinical journal of the American Society of Nephrology : CJASN

    2021  Volume 16, Issue 2, Page(s) 188–190

    MeSH term(s) Hepacivirus ; Hepatitis C/diagnosis ; Hepatitis C/drug therapy ; Humans ; Kidney ; Kidney Transplantation ; Tissue Donors ; United States
    Language English
    Publishing date 2021-01-15
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2226665-3
    ISSN 1555-905X ; 1555-9041
    ISSN (online) 1555-905X
    ISSN 1555-9041
    DOI 10.2215/CJN.19431220
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Increased Rates of Kidney Discard in the Era of COVID-19 and Recent KAS Policy Implementation.

    Özer, Yunus / Kaplan, Salim / Sandikçi, Burhaneddin / Gupta, Gaurav / Tanriover, Bekir

    Transplantation

    2022  Volume 106, Issue 11, Page(s) e503–e506

    MeSH term(s) Humans ; COVID-19/epidemiology ; Tissue and Organ Procurement ; Tissue Donors ; Kidney ; Policy
    Language English
    Publishing date 2022-08-05
    Publishing country United States
    Document type Letter ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 208424-7
    ISSN 1534-6080 ; 0041-1337
    ISSN (online) 1534-6080
    ISSN 0041-1337
    DOI 10.1097/TP.0000000000004321
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Reply.

    AbdulRahim, Nashila / Tanriover, Bekir

    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society

    2019  Volume 25, Issue 4, Page(s) 669–670

    MeSH term(s) Kidney ; Kidney Transplantation ; Liver ; Liver Transplantation ; Transplants
    Language English
    Publishing date 2019-01-07
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2006866-9
    ISSN 1527-6473 ; 1527-6465
    ISSN (online) 1527-6473
    ISSN 1527-6465
    DOI 10.1002/lt.25407
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Recurrent antibody-mediated rejection in renal allograft: physician's dilemma.

    Kotla, Suman Krishna / Tanriover, Bekir

    Journal of nephrology

    2020  Volume 33, Issue 4, Page(s) 661–665

    Abstract: Antibody-mediated rejection is the primary cause of renal allograft failure, and the molecular mechanistic is relatively less known in comparison to cell-mediated rejection. With the advent of new immunological agents, the short-term graft survival ... ...

    Abstract Antibody-mediated rejection is the primary cause of renal allograft failure, and the molecular mechanistic is relatively less known in comparison to cell-mediated rejection. With the advent of new immunological agents, the short-term graft survival outcomes have improved, but the long-term outcomes are still unchanged. We present a case of 47-year-old with end-stage renal disease due to presumed lupus status post deceased donor renal transplantation. The patient developed recurrent (a total of five) antibody-mediated rejections (donor-specific antibody and C4d staining negative) spanning within a year of transplant despite the standard of care therapies. The present case draws attention to the importance of non-HLA antibodies in antibody-mediated rejection and diagnostic tools we can rely on when the histology is inconclusive and the role of new immunological agents.
    MeSH term(s) Allografts ; Graft Rejection/immunology ; Graft Survival/immunology ; Humans ; Isoantibodies/immunology ; Kidney Transplantation ; Middle Aged
    Chemical Substances Isoantibodies
    Language English
    Publishing date 2020-06-18
    Publishing country Italy
    Document type Case Reports ; Journal Article
    ZDB-ID 1093991-x
    ISSN 1724-6059 ; 1120-3625 ; 1121-8428
    ISSN (online) 1724-6059
    ISSN 1120-3625 ; 1121-8428
    DOI 10.1007/s40620-020-00780-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Book ; Online: Large-scale data extraction from the UNOS organ donor documents

    Rychlik, Marek / Tanriover, Bekir / Han, Yan

    2023  

    Abstract: In this paper we focus on three major task: 1) discussing our methods: Our method captures a portion of the data in DCD flowsheets, kidney perfusion data, and Flowsheet data captured peri-organ recovery surgery. 2) demonstrating the result: We built a ... ...

    Abstract In this paper we focus on three major task: 1) discussing our methods: Our method captures a portion of the data in DCD flowsheets, kidney perfusion data, and Flowsheet data captured peri-organ recovery surgery. 2) demonstrating the result: We built a comprehensive, analyzable database from 2022 OPTN data. This dataset is by far larger than any previously available even in this preliminary phase; and 3) proving that our methods can be extended to all the past OPTN data and future data. The scope of our study is all Organ Procurement and Transplantation Network (OPTN) data of the USA organ donors since 2008. The data was not analyzable in a large scale in the past because it was captured in PDF documents known as ``Attachments'', whereby every donor's information was recorded into dozens of PDF documents in heterogeneous formats. To make the data analyzable, one needs to convert the content inside these PDFs to an analyzable data format, such as a standard SQL database. In this paper we will focus on 2022 OPTN data, which consists of $\approx 400,000$ PDF documents spanning millions of pages. The entire OPTN data covers 15 years (2008--20022). This paper assumes that readers are familiar with the content of the OPTN data.
    Keywords Computer Science - Computer Vision and Pattern Recognition ; Electrical Engineering and Systems Science - Image and Video Processing ; 62 ; 68 ; I.5.4
    Subject code 006
    Publishing date 2023-08-30
    Publishing country us
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: Early Data on Utilization and Discard of Organs From COVID-19-infected Donors: A US National Registry Analysis.

    Gupta, Gaurav / Azhar, Ambreen / Gungor, Ahmet / Molnar, Miklos Z / Morales, Megan K / Tanriover, Bekir

    Transplantation

    2022  Volume 106, Issue 5, Page(s) e266–e268

    MeSH term(s) COVID-19 ; Humans ; Registries ; Tissue Donors ; Tissue and Organ Procurement
    Language English
    Publishing date 2022-03-01
    Publishing country United States
    Document type Letter ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 208424-7
    ISSN 1534-6080 ; 0041-1337
    ISSN (online) 1534-6080
    ISSN 0041-1337
    DOI 10.1097/TP.0000000000004091
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Utilization of hepatitis C virus-positive donors in kidney transplantation.

    Shetty, Aneesha / Ariyamuthu, Venkatesh K / Gungor, Ahmet B / Tanriover, Bekir

    Current opinion in organ transplantation

    2022  Volume 28, Issue 1, Page(s) 22–28

    Abstract: Purpose of review: Direct-acting antivirals (DAA) have transformed kidney transplantation by increasing the donor pool from hepatitis C virus (HCV)-infected donors and allowing HCV nucleic acid amplification testing (NAT) donor-positive/recipient- ... ...

    Abstract Purpose of review: Direct-acting antivirals (DAA) have transformed kidney transplantation by increasing the donor pool from hepatitis C virus (HCV)-infected donors and allowing HCV nucleic acid amplification testing (NAT) donor-positive/recipient-negative (D+/R-) transplantation over the last 7 years. Willingness to accept kidneys from HCV-infected donors and timing/duration of DAA therapy have been evolving.
    Recent findings: By 2021, most of the HCV NAT+ kidneys (92.6%) were transplanted to HCV-naive recipients. Despite the availability of effective DAA therapy, the discard rate of HCV NAT kidneys has been stagnant around 25%. The proportion of wait-listed patients willing to accept a deceased donor kidney from HCV Ab+ and HCV NAT+ donors increased 20-fold between 2015 and 2022. Wait-listed time to receive HCV NAT+ kidneys has been rising and most of the kidneys are transplanted to HCV-naive recipients. The proportion of deceased donor kidney transplants performed in recipients with HCV seropositivity decreased from 5.1 to 2.8% during the same period. Relatively short courses of DAA therapy (7-8 days) appear to be effective to decrease HCV transmission (<5%) and achieve sustained virological response at 12 weeks if administered prior to revascularization.
    Summary: Further studies are needed to evaluate long-term outcomes of HCV NAT D+/R- transplantation and the best course of DAA treatment.
    MeSH term(s) Humans ; Kidney Transplantation/adverse effects ; Antiviral Agents/therapeutic use ; Hepacivirus/genetics ; Hepatitis C, Chronic/drug therapy ; Tissue Donors ; Hepatitis C/diagnosis ; Hepatitis C/drug therapy
    Chemical Substances Antiviral Agents
    Language English
    Publishing date 2022-10-13
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 1390429-2
    ISSN 1531-7013 ; 1087-2418
    ISSN (online) 1531-7013
    ISSN 1087-2418
    DOI 10.1097/MOT.0000000000001031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top